Not Tagged
Not Tagged
['aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'leukemia', 'myeloid']
today we are presenting our positive preclinical data for orm-6151 at #ash22. we look forward to advancing our first-in-class anti-cd33 antibody-enabled gspt1 degrader as a potential treatment for acute myeloid #leukemia. #tpd #cancer #oncology 
Orum is a private, clinical stage biotech advancing first-in-class tumor-directed, antibody-enabled targeted protein degraders to improve #cancer treatment.